ALXN
Alexion Pharmaceuticals, Inc.
108.32
-
7.13
6.18%
8 x 108.56
11 x 108.79
bid
ask
12:09 PM
timesize


sentiment
107.14
day range
116.00
92.56
52 week range
141.86
Prev Close115.45
Open115.59
Low107.14
High116.00
Volume1.79M
Avg. Volume1.80M
Market Cap23.96B
Inst. Own96.77%
Beta1.66
Short Ratio2.11
Div & Yield /
EPS6.52
P/E16.60
1yr Target149.45
50day MA107.65
200day MA112.44
^DJI
Dow Jones Industrial Average
27619.01
12:09 PM
-
30.79
0.11%
^IXIC
NASDAQ Composite
8562.07
12:09 PM
-
4.60
0.05%
^GSPC
S&P 500
3111.54
12:09 PM
-
1.22
0.04%
AAPL
Apple Inc.
264.15
12:09 PM
9 x 264.09
9 x 264.09
+
2.41
0.92%
GOOG
Alphabet Inc.
1319.73
12:07 PM
8 x 1319.27
8 x 1319.55
-
0.81
0.06%
AMZN
Amazon.com, Inc.
1747.09
12:07 PM
8 x 1746.88
10 x 1747.44
-
13.60
0.77%
MSFT
Microsoft Corporation
149.92
12:08 PM
9 x 149.84
13 x 149.87
+
0.07
0.05%
FB
Facebook, Inc.
198.99
12:08 PM
8 x 198.61
8 x 198.63
+
0.28
0.14%
BABA
Alibaba Group Holding Limited
199.12
12:08 PM
8 x 199.88
9 x 199.90
+
5.38
2.78%
NFLX
Netflix, Inc.
300.98
12:08 PM
14 x 299.07
9 x 298.97
-
3.34
1.10%
TSLA
Tesla, Inc.
330.39
12:05 PM
8 x 330.38
9 x 330.46
-
2.64
0.79%
NVDA
NVIDIA Corporation
208.42
12:08 PM
9 x 208.74
8 x 208.71
-
1.00
0.48%
AMD
Advanced Micro Devices, Inc.
39.94
12:09 PM
18 x 39.98
9 x 39.99
+
0.25
0.63%
MU
Micron Technology, Inc.
46.43
12:08 PM
9 x 46.51
8 x 46.52
+
0.13
0.28%
SPY
SPDR S&P 500 ETF Trust
311.38
12:08 PM
11 x 311.36
10 x 311.37
-
0.08
0.03%
TQQQ
ProShares UltraPro QQQ
74.56
12:02 PM
22 x 74.35
8 x 74.36
-
0.08
0.11%
BRK-A
Berkshire Hathaway Inc.
328135.10
12:00 PM
12 x 328195.00
8 x 328497.75
+
634.10
0.19%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
-
0
Views -
In Search of Profitable Stocks: Alexion Pharmaceuticals Inc. (ALXN), Lincoln National Corporation (LNC)
Market Recorder •0
Views -
S&P 500 Movers: ALXN, TSCO
Nasdaq •0
Views -
Nasdaq 100 Movers: ALXN, DLTR
Nasdaq •0
Views -
Taking a Deep Dive into the Numbers & Valuation: McKesson Corporation (NYSE:MCK), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)
Beloit Bulletin •0
Views -
Voya Investment Management LLC Sells 864 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Slater Sentinel •0
Views -
Hot Stock's Highlights :: Alexion Pharmaceuticals, Inc.,(NASDAQ:ALXN)
Money Making News •0
Views -
Zacks: Analysts Expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to Announce $2.52 EPS
TechNewsObserver •0
Views -
Latest Alterations:- News Planets
Alexion Pharmaceuticals, Inc., (NASDAQ: ALXN) •0
Views -
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Expected to Post Earnings of $2.52 Per Share
Mitchell Messenger •0
Views -
McKesson Corporation (NYSE:MCK), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN) Quant Scorecard In Focus
Cora Courier •0
Views -
Under the Trendline, Stock Looks for a New-Year Reversal: Sharps Compliance Corp. (NASDAQ:SMED)
Alta Advocate •0
Views -
Drilling into the Technicals & Valuation For Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)
Stock Minute •0
Views -
0
Views -
Reviewing Alexion Pharmaceuticals Inc. (ALXN)'s and Its Rivals results
The Broch Herald •0
Views -
Did Hedge Funds Drop The Ball On State Street Corporation (STT) ?
Insider Monkey •0
Views -
Too Sour Or Too Delicious?-:-Danaher Corporation, (NYSE: DHR), Alexion Pharmaceuticals, Inc., (NASDAQ: ALXN)
Ws News Publisher •0
Views -
Recent Fundamentals:: Alexion Pharmaceuticals, Inc., (NASDAQ: ALXN)
Times Of New York •0
Views -
Is Microchip Technology Incorporated (MCHP) A Good Stock To Buy?
Insider Monkey •0
Views -
0
Views -
0
Views -
0
Views -
Monetizing This Stock Might Help U Boost Your Portfolio :: Alexion Pharmaceuticals, Inc.,(NASDAQ:ALXN)
Money Making News •0
Views -
0
Views -
Eye Catching Stock: Alexion Pharmaceuticals (NASDAQ:ALXN)
WEB NEWS OBSERVER •0
Views -
Signition LP Takes $369,000 Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Mitchell Messenger •0
Views -
Huntington National Bank Sells 1,091 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
TechNewsObserver •0
Views -
Tower Research Capital LLC TRC Acquires 1,875 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Mitchell Messenger •0
Views -
SG Americas Securities LLC Acquires 29,691 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Mitchell Messenger •0
Views -
0
Views -
Priming the Pump: What Are Analysts Saying About Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)?
Alta Advocate •0
Views
Profile
...
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2019-10-23 | 2019-09 | 2.49 | 2.79 | 0.3 | 12.05% |
2019-07-24 | 2019-06 | 2.36 | 2.64 | 0.28 | 11.86% |
2019-04-25 | 2019-03 | 2.19 | 2.39 | 0.2 | 9.13% |
2019-02-04 | 2018-12 | 1.83 | 2.14 | 0.31 | 16.94% |
2018-10-24 | 2018-09 | 1.75 | 2.02 | 0.27 | 15.43% |
2018-07-26 | 2018-06 | 1.69 | 2.07 | 0.38 | 22.49% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2019-11-11 | SunTrust Robinson Humphrey | Upgrade | Buy | |
2019-10-23 | Raymond James | Upgrade | Outperform | |
2019-10-10 | Morgan Stanley | Upgrade | Overweight | |
2019-09-25 | William Blair | Upgrade | Outperform | |
2019-09-11 | BMO Capital | Upgrade | Outperform | |
2019-09-05 | Credit Suisse | Upgrade | Outperform |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-05-29 | BAKER BROS ADVISORS L P | Director | 0.00 | Sale |
2019-05-14 | BRENNAN DAVID R | Director | 11.64K | Stock Award(Grant) |
2019-11-28 | CARINO TANISHA | Officer | 8.78K | Stock Award(Grant) |
2019-05-14 | COUGHLIN CHRISTOPHER J | Director | 33.41K | Stock Award(Grant) |
2019-05-14 | DUNSIRE DEBORAH | Director | 7.73K | Stock Award(Grant) |
2019-05-14 | FRIEDMAN PAUL A | Director | 6.88K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2019-09-29 | FMR, LLC | 19.59M | 1.92B | 8.85% |
2019-09-29 | Vanguard Group, Inc. (The) | 16.85M | 1.65B | 7.61% |
2019-09-29 | Blackrock Inc. | 15.96M | 1.56B | 7.21% |
2019-09-29 | Price (T.Rowe) Associates Inc | 11.88M | 1.16B | 5.37% |
2019-09-29 | State Street Corporation | 10.87M | 1.06B | 4.91% |
2019-09-29 | Baker Brothers Advisors, LLC | 8.26M | 808.80M | 3.73% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2019-06-29 | Vanguard Total Stock Market Index Fund | 5.85M | 766.75M | 2.65% |
2019-06-29 | Vanguard 500 Index Fund | 4.41M | 577.81M | 1.99% |
2019-06-29 | Price (T.Rowe) Blue Chip Growth Fund Inc. | 3.09M | 405.31M | 1.40% |
2019-06-29 | Harbor Capital Appreciation Fund | 3.00M | 392.61M | 1.35% |
2019-08-30 | SPDR S&P 500 ETF Trust | 2.40M | 242.08M | 1.09% |
2019-08-30 | iShares NASDAQ Biotechnology ETF | 2.16M | 218.02M | 0.98% |
Split
...
Split | Date |
---|---|
2 : 1 | 2011-05-23 |
2 : 1 | 2008-08-25 |